Key result
Maternal application of topical diclofenac patches during the second and third trimesters of pregnancy was associated with antenatal closure of the ductus arteriosus and persistent pulmonary hypertension of the newborn.
Why the study?
NSAID use during the third trimester can cause premature constriction of the ductus arteriosus, but cases following maternal topical use require documentation.
Does maternal topical use of diclofenac during pregnancy cause premature constriction of the ductus arteriosus and persistent pulmonary hypertension of the newborn?
Comparison
Maternal topical Diclofenac-Epolamine 140 mg patch during pregnancy
Design
Case report
Follow-up
Day 48
Authors
Loading...
May warrant caution with topical diclofenac in later pregnancy; hypothesis-generating case report requiring confirmation.
Case Report (n=1)
No
Does maternal topical use of diclofenac during pregnancy cause premature constriction of the ductus arteriosus and persistent pulmonary hypertension of the newborn?
Maternal use of topical diclofenac during the second and third trimesters of pregnancy can lead to severe fetal and neonatal complications, including premature closure of the ductus arteriosus and persistent pulmonary hypertension of the newborn.
Duc et al. (2021) conducted a case report in Persistent Pulmonary Hypertension of the Newborn (PPHN) (n=1). Topical Diclofenac (Diclofenac-Epolamine 140 mg patch) was evaluated on Development of PPHN and narrowing of the ductus arteriosus. Maternal application of topical diclofenac patches during the second and third trimesters of pregnancy was associated with antenatal closure of the ductus arteriosus and persistent pulmonary hypertension of the newborn.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: